Fieldview Capital Management LLC Makes New $785,000 Investment in Halozyme Therapeutics, Inc. $HALO

Fieldview Capital Management LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 10,705 shares of the biopharmaceutical company’s stock, valued at approximately $785,000.

A number of other hedge funds and other institutional investors have also modified their holdings of HALO. Empowered Funds LLC acquired a new position in Halozyme Therapeutics during the first quarter worth $755,000. Acadian Asset Management LLC acquired a new stake in shares of Halozyme Therapeutics in the first quarter worth about $195,000. Profund Advisors LLC lifted its position in shares of Halozyme Therapeutics by 40.2% in the second quarter. Profund Advisors LLC now owns 38,440 shares of the biopharmaceutical company’s stock worth $2,000,000 after buying an additional 11,021 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Halozyme Therapeutics by 607.1% during the 2nd quarter. Allworth Financial LP now owns 9,405 shares of the biopharmaceutical company’s stock worth $489,000 after acquiring an additional 8,075 shares in the last quarter. Finally, Boston Partners boosted its stake in shares of Halozyme Therapeutics by 3.6% during the 2nd quarter. Boston Partners now owns 431,345 shares of the biopharmaceutical company’s stock worth $23,062,000 after acquiring an additional 15,020 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $67.81 on Wednesday. The business has a 50 day moving average price of $72.64 and a 200 day moving average price of $70.67. Halozyme Therapeutics, Inc. has a twelve month low of $47.50 and a twelve month high of $82.22. The company has a market cap of $8.00 billion, a price-to-earnings ratio of 27.23, a PEG ratio of 0.28 and a beta of 0.98. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business had revenue of $451.77 million during the quarter, compared to the consensus estimate of $446.13 million. During the same period in the prior year, the firm earned $1.26 earnings per share. The business’s quarterly revenue was up 51.6% on a year-over-year basis. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total transaction of $140,500.00. Following the transaction, the director owned 40,123 shares of the company’s stock, valued at approximately $2,818,640.75. The trade was a 4.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Helen Torley sold 10,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $70.21, for a total transaction of $702,100.00. Following the transaction, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $53,905,833.80. The trade was a 1.29% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 90,857 shares of company stock worth $6,500,287. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on HALO shares. Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research note on Thursday, February 19th. The Goldman Sachs Group reiterated a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Benchmark boosted their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Finally, Weiss Ratings downgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. Six research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $78.56.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.